- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04011995
Effects of Intermittent Caloric Restriction in Youth With Cardiometabolic Risk
Effects of Intermittent Caloric Restriction in Youth With Cardiometabolic Risk: a Randomized Controlled Pilot Study
Study Overview
Status
Conditions
Detailed Description
The National China Health and Nutrition Survey revealed that 42% of overweight children had at least one cardiovascular metabolic risk, such as hyperglycaemia, dyslipidemia or hypertension. Non-pharmaceutical life style modifications are the recommended intervention to these subjects, including caloric restriction and increased physical activity. However, the problems of poor compliance and metabolic adaptation are well known. Evidences from a number studies in rodent models and human indicated that intermittent caloric restriction (ICR) may stimulate series reactions in human body, including improvement of insulin sensitivity, blood pressure, oxidative stress and inflammation, and may be easier to follow. Evidence from larger human studies is strongly encouraged, while the effects, safety and adherence in chidren and youth need to be studied.
This study is a randomized controlled trial of intermittent caloric restriction versus low carbohydrate diet in youth with cardiometabolic risk over one month period. The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week. For control group, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention during the 14-day intervention period,. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day. Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted.
The study aim to explore effects of the dietary interventions on cardiometabolic markers, inflammatory reaction, oxidative stress and gut microbiome in youth with cardiometabolic risk.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Children's Hospital of Fudan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Have at least one of the following cardiometabolic abnormalities:
- Overweight or obesity (central obesity or general obesity)
- Prediabetes: impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT)
- Dyslipidemia
- Elevated blood pressure
Criteria for cardiometabolic abnormalities:
Overweight or obesity
For subjects (9 ≤ age ≤ 18 years) :
• General obesity: Body mass index higher than the 85th percentile for overweight and the 90th percentile for obesity, based on the references for screening overweight and obesity in Chinese children and adolescents.
• Central obesity: Waist circumference higher than the 90th percentile of the age and gender-specific reference for screening cardiovascular risk factors in Chinese children and adolescents.
For subjects ( 19 ≤ age ≤ 30 years) :
• General obesity: Body mass index between 24.0 and 27.9 kg/m2 for overweight and ≥28 kg/m2 for obesity.
• Central obesity: Waist circumference ≥85cm for men and ≥80cm for female. Based on recommendation of overweight and obesity in Chinese adults.
Prediabetes:
With IFG and/or IGT. IFG: fasting glucose from 5.6 to 6.9 mmol/L; IGT: 2-h glucose in the 75g oral glucose tolerance test from 7.8 to 11.0 mmol/L.
Based on recommendation of American Diabetes Association.
Dyslipidemia:
For subjects (9 ≤ age ≤ 18 years) :
Triglycerides of ≥1.70 mmol/L or total cholesterol of ≥5.18 mmol/L or lowdensity lipoprotein cholesterol ≥3.37 mmol/L or highdensity lipoprotein cholesterol of ≤1.04 mmol/L. Based on recommendation in Chinese children and adolescents.
For subjects ( 19 ≤ age ≤ 30 years) :
Triglycerides of ≥1.7 mmol/L or total cholesterol of ≥5.2 mmol/L or lowdensity lipoprotein cholesterol ≥3.4 mmol/L or highdensity lipoprotein cholesterol of ≤1.0 mmol/L. Based on guideline for the management of dyslipidemia in Chinese adults.
- Elevated blood pressure:
For subjects (9 ≤ age ≤ 18 years) :
Blood pressure higher than the 90th percentile of blood pressure age and gender-specific reference standards for Chinese children and adolescents, or blood pressure >120/80 mmHg.
For subjects ( 19 ≤ age ≤ 30 years) :
Systolic blood pressure≥120 mmHg and/or diastolic blood pressure ≥80 mmHg. Based on Chinese guidelines for the management of hypertension.
Exclusion Criteria:
- Diagnosis of severe diseases such as cardiac insufficiency, severe malnutrition or immunodeficiency.
- History of bariatric surgery.
- Use of antiobesity drugs or supplements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Low carbohydrate diet
|
Health education is conducted once a week during 14-day dietary intervention for all subjects.
Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day. Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted. |
Experimental: Intermittent caloric restriction
|
The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week. Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted.
Other Names:
Health education is conducted once a week during 14-day dietary intervention for all subjects.
Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reversal of cardiometabolic abnormalities
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
The primary outcome is a composite outcome that will be measured by combining multiple reverse outcomes of the following cardiometabolic abnormalities: (1) overweight or obesity, (2) prediabetes, (3) hyperlipidemia and (4) elevated blood pressure. It is defined as occurring if any cardiometabolic abnormality has a reversal outcome at the 14th day of dietary intervention phase. Reversal of cardiometabolic abnormalities is defined as: At the 14th day of dietary intervention phase, at least one of the following indicators changed from abnormal at baseline to normal: overweight, obesity, prediabetes, hyperlipidemia and elevated blood pressure. (The reversal of overweight or obesity is defined according to reference[1, 2]: For subject with general obesity at baseline: weight loss of 1.5 kg after intervention; For subject with central obesity at baseline: waist circumference reduction of 1.5 cm after intervention.) |
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in insulin
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Serum from fasting blood sample is used for measurement of insulin.
|
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Change in insulin-like growth factor-1
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Fasting blood sample for measurement of insulin-like growth factor-1.
|
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Change in mean blood glucose
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Measured by a blood glucose monitor for 24-hour glucose monitoring during the 14-day intervention phase.
|
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Change in gut microbial compositions
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Stool sample of subject is used for measurement of gut microbial compositions.
|
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Change in body weight
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Body weight is measured according to the Physical Fitness and Health Surveillance of Chinese School Students by trained, certified study staff.
It is measured to the nearest 0.1 kg.
|
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Change in body weight
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the self-maintenance phase.
|
Body weight is measured by subject and reported by electronic questionnaire.
It is measured to the nearest 0.1 kg.
|
From the baseline (the first day of the intervention phase) to the 14th day of the self-maintenance phase.
|
Change in waist circumference
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Waist circumference is measured to the nearest 0.1 cm using a constant tension tape around the waist at 1 cm below the navel as the subject exhaled.
It is calculated as the average value of two measurements.
|
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Change in waist circumference
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the self-maintenance phase.
|
Waist circumference is measured by subject and reported by electronic questionnaire.
It is measured to the nearest 0.1 cm using a constant tension tape around the waist at 1 cm below the navel as the subject exhaled.
It is calculated as the average value of two measurements.
|
From the baseline (the first day of the intervention phase) to the 14th day of the self-maintenance phase.
|
Dietary energy intake
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Daily dietary energy intake (kcals/day) is calculated by researchers using food weighing photos of the subject.
|
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Self-reported dietary adherence
Time Frame: At the 14th day of the self-maintenance phase.
|
Adherence to diet will be assessed with a electronic questionnaire in the self-maintenance phase.
|
At the 14th day of the self-maintenance phase.
|
Change in monocyte chemoattractant protein-1 (MCP-1)
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
MCP-1 will be measured by enzyme-linked immunosorbent assays (R&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention.
|
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Change in free fatty acid (FFA)
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
FFA will be measured by enzyme-linked immunosorbent assays (R&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention.
|
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Change in fibroblast growth factor 21 (FGF-21)
Time Frame: From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
FGF-21 will be measured by enzyme-linked immunosorbent assays (R&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention.
|
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase.
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Arnason TG, Bowen MW, Mansell KD. Effects of intermittent fasting on health markers in those with type 2 diabetes: A pilot study. World J Diabetes. 2017 Apr 15;8(4):154-164. doi: 10.4239/wjd.v8.i4.154.
- Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG, Son TG, Maudsley S, Carlson OD, Egan JM, Flyvbjerg A, Howell A. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011 May;35(5):714-27. doi: 10.1038/ijo.2010.171. Epub 2010 Oct 5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICR_2019_2.0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Intermittent caloric restriction
-
Central Hospital, Nancy, FranceRecruitingCrohn's DiseaseFrance
-
Karachi Medical and Dental CollegeAziz Medical CenterCompletedWeight Loss | Polycystic Ovarian Syndrome | Intermittent FastingPakistan
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
PfizerUniversity of Adelaide; Royal Adelaide HospitalCompleted
-
Federal University of Minas GeraisRecruiting
-
Coastal Carolina UniversityCompleted
-
Karolinska University HospitalCompleted
-
Centre d'Alt RendimentCompleted
-
Korea UniversityEulji University HospitalCompletedOverweight | Type 2 DiabetesKorea, Republic of
-
University Hospital, MontpellierUnknownType 2 Diabetes | Severe ObesityFrance